Carmine, Takeda use extracellular vesicles for rare disease gene therapies

By The Science Advisory Board staff writers

Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.

The firms will use Carmine's Regent red blood cell extracellular vesicles platform to research, develop, and commercialize nonviral gene therapies for two rare disease targets. Takeda has also committed a $5 million convertible loan to support development of the Regent platform.

In addition, Carmine will receive an upfront payment, research funding support, and potentially over $900 million in total milestone payments plus tiered royalties, the company said. Takeda has gained an option to license the programs following completion of preclinical proof-of-concept studies and would be responsible for clinical development and commercialization, according to Carmine.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: